<table class="naaccr-summary-table naaccr-borders">
  <tr>
    <th class="naaccr-summary-header naaccr-borders">Item #</th>
    <th class="naaccr-summary-header naaccr-borders">Length</th>
    <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
    <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
    <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
  </tr>
  <tr>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1,634</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">SEER</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2021</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">21</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
  </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.neoadjuvTherapyTreatmentEffect<br/><br/>

<div class='content chap10-para-head'><strong>Description</strong></div>
<div class='content chap10-para'>
<p>This data item records the pathologistâ€™s statement of neoadjuvant treatment effect on the primary tumor from the surgical pathology report. Whenever treatment effect definitions are recommended by or available in CAP Cancer Protocols, this data item follows the CAP definitions indicating absent or present effect. When specific CAP definitions are not available, registrars should use treatment effect general use categories.</p>

</div>

<div class='content chap10-para-head'><strong>Rationale</strong></div>
<div class='content chap10-para'>
<p>This data item provides information related to the quality of care and describes the pathological outcomes after neoadjuvant therapy. This data item provides prognostically relevant information by quantifying the extent of therapy-induced tumor regression. Therefore, this item can provide a better risk stratification for patients who received neoadjuvant therapy. In addition, this data item can contribute to assessments of cancer care quality.</p>

</div>



<div class='content chap10-para'><p><strong>Codes</strong></p>
</div>
<table>
        <tr class='code-row'><td class='code-nbr'>0</td><td class='code-desc'>Neoadjuvant therapy not given/no known presurgical therapy</td></tr>
        <tr class='code-row'><td class='code-nbr'>1-4</td><td class='code-desc'>Site-specific code; type of response</td></tr>
        <tr class='code-row'><td class='code-nbr'>6</td><td class='code-desc'>Neoadjuvant therapy completed and surgical resection performed, response not documented or unknown  
 Cannot be determined</td></tr>
        <tr class='code-row'><td class='code-nbr'>7</td><td class='code-desc'>Neoadjuvant therapy completed and planned surgical resection not performed</td></tr>
        <tr class='code-row'><td class='code-nbr'>9</td><td class='code-desc'>Unknown if neoadjuvant therapy performed  
 Unknown if planned surgical procedure performed after completion of neoadjuvant therapy  
 Death Certificate only (DCO)</td></tr>
</table>

